{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T01:04:46Z","timestamp":1768266286736,"version":"3.49.0"},"reference-count":74,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>COVID-19 convalescent plasma (CCP) has been explored as one of the treatment options for COVID-19. Results of many cohort studies and clinical trials have been recently published. At first glance, the results of the CCP studies appear to be inconsistent. However, it became clear that CCP is not beneficial if CCP with low anti-SARS-CoV-2 antibody concentrations is used, if it is administered late in advanced disease stages, and to patients who already mounted an antibody response against SARS-CoV-2 at the time of CCP transfusion. On the other hand, CCP may prevent progression to severe COVID-19 when very high-titer CCP is given early in vulnerable patients. Immune escape of new variants is a challenge for passive immunotherapy. While new variants of concern developed resistance to most clinically used monoclonal antibodies very rapidly, immune plasma from individuals immunized by both a natural SARS-CoV-2 infection and SARS-CoV-2 vaccination retained neutralizing activity against variants. This review briefly summarizes the evidence on CCP treatment to date and identifies further research needs. Ongoing research on passive immunotherapy is not only relevant for improving care for vulnerable patients in the ongoing SARS-CoV-2 pandemic, but even more as a model for passive immunotherapy in case of future pandemics with a newly evolving pathogen. Compared to other drugs, which must be newly developed in a pandemic (e.g., monoclonal antibodies, antiviral drugs), convalescent plasma is rapidly available, inexpensive to produce, and can be adaptive to viral evolution by selection of contemporary convalescent donors.<\/jats:p>","DOI":"10.1055\/a-1987-3682","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T23:30:45Z","timestamp":1676935845000},"page":"067-074","source":"Crossref","is-referenced-by-count":4,"title":["Immune Plasma for the Treatment of COVID-19: Lessons Learned so far"],"prefix":"10.1055","volume":"43","author":[{"given":"Hubert","family":"Schrezenmeier","sequence":"additional","affiliation":[{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg-Hessen, and, University Hospital Ulm, Ulm, Germany"},{"name":"Institute of Transfusion Medicine, University of Ulm, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg-Hessen, and, University Hospital Ulm, Ulm, Germany"},{"name":"Institute of Transfusion Medicine, University of Ulm, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrike","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg-Hessen, and, University Hospital Ulm, Ulm, Germany"},{"name":"Institute of Transfusion Medicine, University of Ulm, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Appl","sequence":"additional","affiliation":[{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg-Hessen, and, University Hospital Ulm, Ulm, Germany"},{"name":"Institute of Transfusion Medicine, University of Ulm, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Jahrsd\u00f6rfer","sequence":"additional","affiliation":[{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg-Hessen, and, University Hospital Ulm, Ulm, Germany"},{"name":"Institute of Transfusion Medicine, University of Ulm, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erhard","family":"Seifried","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine and Immunohematology, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg \u2013 Hessen, Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sixten","family":"K\u00f6rper","sequence":"additional","affiliation":[{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg-Hessen, and, University Hospital Ulm, Ulm, Germany"},{"name":"Institute of Transfusion Medicine, University of Ulm, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1111\/bjh.16935","article-title":"Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience","volume":"190","author":"V Shah","year":"2020","journal-title":"Br J Haematol"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5501\/wjv.v11.i4.204","article-title":"Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: warrants a clear therapeutic strategy","volume":"11","author":"T Sahu","year":"2022","journal-title":"World J Virol"},{"issue":"05","key":"ref3","doi-asserted-by":"crossref","first-page":"e2210880","DOI":"10.1001\/jamanetworkopen.2022.10880","article-title":"Differences in outcomes and factors associated with mortality among patients with SARS-CoV-2 infection and cancer compared with those without cancer: a systematic review and meta-analysis","volume":"5","author":"E Khoury","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood.2021012251","article-title":"COVID-19 in patients with hematologic malignancy","volume":"140","author":"P Langerbeins","year":"2022","journal-title":"Blood"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"A Casadevall","year":"2020","journal-title":"J Clin Invest"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI138745","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","volume":"130","author":"E M Bloch","year":"2020","journal-title":"J Clin Invest"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/vox.12926","article-title":"Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?","volume":"115","author":"P Tiberghien","year":"2020","journal-title":"Vox Sang"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"J Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa2031893","article-title":"Convalescent plasma antibody levels and the risk of death from COVID-19","volume":"384","author":"M J Joyner","year":"2021","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"m3516","DOI":"10.1136\/bmj.m3516","article-title":"Convalescent plasma for COVID-19","volume":"370","author":"L J Estcourt","year":"2020","journal-title":"BMJ"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"e0092622","DOI":"10.1128\/spectrum.00926-22","article-title":"Susceptibility of SARS-CoV-2 omicron variants to therapeutic monoclonal antibodies: systematic review and meta-analysis","volume":"10","author":"K Tao","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1038\/s41598-022-22431-6","article-title":"Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: a Bayesian network meta-analysis","volume":"12","author":"D McConnell","year":"2022","journal-title":"Sci Rep"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients","volume":"386","author":"A Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"ref15","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"J Hammond","year":"2022","journal-title":"N Engl J Med"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe COVID-19 in Outpatients","volume":"386","author":"R L Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"e2341","DOI":"10.1002\/rmv.2341","article-title":"Passive immunotherapies for COVID-19: The subtle line between standard and hyperimmune immunoglobulins is getting invisible","volume":"32","author":"D Focosi","year":"2022","journal-title":"Rev Med Virol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0140-6736(22)00101-5","article-title":"Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial","volume":"399","author":"ITAC (INSIGHT 013) Study Group","year":"2022","journal-title":"Lancet"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial","volume":"324","author":"L Li","year":"2020","journal-title":"JAMA"},{"issue":"17","key":"ref20","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.2021.18178","article-title":"Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial","volume":"326","author":"L J Estcourt","year":"2021","journal-title":"JAMA"},{"issue":"24","key":"ref21","first-page":"131","article-title":"A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia","volume":"131","author":"K J Bar","year":"2021","journal-title":"J Clin Invest"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3201\/eid2803.212299","article-title":"High-dose convalescent plasma for treatment of severe COVID-19","volume":"28","author":"G C De Santis","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"m3939","DOI":"10.1136\/bmj.m3939","article-title":"Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)","volume":"371","author":"A Agarwal","year":"2020","journal-title":"BMJ"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"9927","DOI":"10.1038\/s41598-021-89444-5","article-title":"Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease","volume":"11","author":"M AlQahtani","year":"2021","journal-title":"Sci Rep"},{"issue":"07","key":"ref26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A randomized trial of convalescent plasma in COVID-19 severe pneumonia","volume":"384","author":"V A Simonovich","year":"2021","journal-title":"N Engl J Med"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1186\/s13104-021-05847-7","article-title":"Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden","volume":"14","author":"K Holm","year":"2021","journal-title":"BMC Res Notes"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"e2136246","DOI":"10.1001\/jamanetworkopen.2021.36246","article-title":"Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial","volume":"4","author":"F Menichetti","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/bmjresp-2021-001017","article-title":"Efficacy of convalescent plasma for treatment of COVID-19 in Uganda","volume":"8","author":"B Kirenga","year":"2021","journal-title":"BMJ Open Respir Res"},{"issue":"21","key":"ref30","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJMoa2103784","article-title":"Early convalescent plasma for high-risk outpatients with COVID-19","volume":"385","author":"F K Korley","year":"2021","journal-title":"N Engl J Med"},{"key":"ref32","first-page":"16957608","article-title":"Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial","author":"Y Ray","year":"2020","journal-title":"medRxiv"},{"issue":"02","key":"ref33","doi-asserted-by":"crossref","first-page":"2101724","DOI":"10.1183\/13993003.01724-2021","article-title":"Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma","volume":"59","author":"T Devos","year":"2022","journal-title":"Eur Respir J"},{"issue":"02","key":"ref34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/jamainternmed.2021.6850","article-title":"Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial","volume":"182","author":"M B Ortigoza","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"20","key":"ref35","doi-asserted-by":"crossref","first-page":"e152264","DOI":"10.1172\/JCI152264","article-title":"Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19","volume":"131","author":"S K\u00f6rper","year":"2021","journal-title":"J Clin Invest"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"2101471","DOI":"10.1183\/13993003.01471-2021","article-title":"Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial","volume":"59","author":"L Sekine","year":"2022","journal-title":"Eur Respir J"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41591-021-01488-2","article-title":"Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial","volume":"27","author":"P B\u00e9gin","year":"2021","journal-title":"Nat Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"Lancet"},{"issue":"03","key":"ref39","doi-asserted-by":"crossref","first-page":"e1003415","DOI":"10.1371\/journal.pmed.1003415","article-title":"Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial","volume":"18","author":"M E Balcells","year":"2021","journal-title":"PLoS Med"},{"issue":"13","key":"ref40","doi-asserted-by":"crossref","first-page":"e150646","DOI":"10.1172\/JCI150646","article-title":"A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19","volume":"131","author":"M R O'Donnell","year":"2021","journal-title":"J Clin Invest"},{"issue":"04","key":"ref41","doi-asserted-by":"crossref","first-page":"e055189","DOI":"10.1136\/bmjopen-2021-055189","article-title":"Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial)","volume":"12","author":"M Bajpai","year":"2022","journal-title":"BMJ Open"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"16385","DOI":"10.1038\/s41598-022-19629-z","article-title":"A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia","volume":"12","author":"L Thorlacius-Ussing","year":"2022","journal-title":"Sci Rep"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1038\/s41598-022-06221-8","article-title":"Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)","volume":"12","author":"K van den Berg","year":"2022","journal-title":"Sci Rep"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.20.20234","article-title":"Prevention of severe COVID-19 in the elderly by early high-titer plasma","author":"R Libster","year":"2020","journal-title":"medRxiv"},{"issue":"18","key":"ref45","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa2119657","article-title":"Early outpatient treatment for COVID-19 with convalescent plasma","volume":"386","author":"D J Sullivan","year":"2022","journal-title":"N Engl J Med"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1038\/s41467-022-29911-3","article-title":"Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients","volume":"13","author":"P Millat-Martinez","year":"2022","journal-title":"Nat Commun"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S2213-2600(21)00545-2","article-title":"High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial","volume":"10","author":"A Alemany","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"09","key":"ref49","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.7326\/M22-1079","article-title":"Clinical practice guidelines from the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 convalescent plasma","volume":"175","author":"L J Estcourt","year":"2022","journal-title":"Ann Intern Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.29.20162917","article-title":"Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy","author":"S A Klassen","year":"2020","journal-title":"medRxiv"},{"issue":"08","key":"ref51","doi-asserted-by":"crossref","first-page":"102898","DOI":"10.1016\/j.isci.2021.102898","article-title":"Effect of time and titer in convalescent plasma therapy for COVID-19","volume":"24","author":"P de Candia","year":"2021","journal-title":"iScience"},{"issue":"07","key":"ref52","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe COVID-19 in older adults","volume":"384","author":"R Libster","year":"2021","journal-title":"N Engl J Med"},{"issue":"01","key":"ref53","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1038\/s41467-021-23469-2","article-title":"Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection","volume":"12","author":"A Gharbharan","year":"2021","journal-title":"Nat Commun"},{"issue":"27","key":"ref54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2807\/1560-7917.ES.2021.26.27.2100568","article-title":"SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data","volume":"26","author":"D Nguyen","year":"2021","journal-title":"Euro Surveill"},{"issue":"05","key":"ref55","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/vox.13060","article-title":"Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary","volume":"116","author":"E Wouters","year":"2021","journal-title":"Vox Sang"},{"issue":"23","key":"ref56","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with COVID-19","volume":"385","author":"D M Weinreich","year":"2021","journal-title":"N Engl J Med"},{"issue":"05","key":"ref57","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.cmi.2022.01.026","article-title":"Evidence-based dosing of convalescent plasma for COVID-19 in future trials","volume":"28","author":"B JA Rijnders","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"e163657","DOI":"10.1172\/JCI163657","article-title":"One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients","author":"S K\u00f6rper","year":"2022","journal-title":"J Clin Invest"},{"issue":"08","key":"ref59","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.ajpath.2020.05.014","article-title":"Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma","volume":"190","author":"E Salazar","year":"2020","journal-title":"Am J Pathol"},{"issue":"12","key":"ref60","doi-asserted-by":"crossref","first-page":"e158190","DOI":"10.1172\/JCI158190","article-title":"Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response","volume":"132","author":"M Marconato","year":"2022","journal-title":"J Clin Invest"},{"issue":"20","key":"ref62","doi-asserted-by":"crossref","first-page":"e152740","DOI":"10.1172\/JCI152740","article-title":"A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia","volume":"131","author":"C Avenda\u00f1o-Sol\u00e1","year":"2021","journal-title":"J Clin Invest"},{"issue":"26","key":"ref63","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1056\/NEJMc2031670","article-title":"Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer","volume":"383","author":"T Aydillo","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"ref64","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.immuni.2022.09.006","article-title":"SARS-CoV-2 in immunocompromised individuals","volume":"55","author":"S DeWolf","year":"2022","journal-title":"Immunity"},{"issue":"05","key":"ref65","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1111\/bjh.16935","article-title":"Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience","volume":"190","author":"V Shah","year":"2020","journal-title":"Br J Haematol"},{"issue":"08","key":"ref66","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19","volume":"7","author":"M A Thompson","year":"2021","journal-title":"JAMA Oncol"},{"issue":"04","key":"ref67","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41375-022-01511-6","article-title":"Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis","volume":"36","author":"T Hueso","year":"2022","journal-title":"Leukemia"},{"issue":"03","key":"ref68","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/v13030436","article-title":"Early administration of convalescent plasma improves survival in patients with hematological malignancies and COVID-19","volume":"13","author":"M M Biernat","year":"2021","journal-title":"Viruses"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1097\/TP.0000000000003962","article-title":"Efficacy of convalescent plasma to treat mild to moderate COVID-19 in kidney transplant patients: a propensity score matching analysis","volume":"106","author":"M P Cristelli","year":"2022","journal-title":"Transplantation"},{"key":"ref71","first-page":"357146","article-title":"A randomized controlled clinical trial demonstrates that plasma from convalescent and vaccinated donors improves outcome of COVID-19 in patients with hematological disease, cancer or immunosuppression","author":"C M\u00fcller-Tidow","year":"2022","journal-title":"EHA Library"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection","volume":"595","author":"Z Wang","year":"2021","journal-title":"Nature"},{"issue":"25","key":"ref75","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1056\/NEJMc2104036","article-title":"Neutralizing response against variants after SARS-CoV-2 infection and one dose of BNT162b2","volume":"384","author":"Y Lustig","year":"2021","journal-title":"N Engl J Med"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1126\/science.abg9175","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"372","author":"L Stamatatos","year":"2021","journal-title":"Science"},{"issue":"07","key":"ref77","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1056\/NEJMc2119236","article-title":"SARS-CoV-2 omicron variant neutralization in serum from vaccinated and convalescent persons","volume":"386","author":"A R\u00f6ssler","year":"2022","journal-title":"N Engl J Med"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"104158","DOI":"10.1016\/j.ebiom.2022.104158","article-title":"Limited neutralisation of the SARS-CoV-2 omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies","volume":"82","author":"A Wilhelm","year":"2022","journal-title":"EBioMedicine"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the omicron variant of SARS-CoV-2","volume":"602","author":"L Liu","year":"2022","journal-title":"Nature"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 omicron to antibody neutralization","volume":"602","author":"D Planas","year":"2022","journal-title":"Nature"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift","volume":"602","author":"E Cameroni","year":"2022","journal-title":"Nature"},{"issue":"27","key":"ref83","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2807\/1560-7917.ES.2021.26.27.2100568","article-title":"SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data","volume":"26","author":"D Nguyen","year":"2021","journal-title":"Euro Surveill"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1987-3682.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T23:32:33Z","timestamp":1676935953000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1987-3682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":74,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2023,2,20]]},"published-print":{"date-parts":[[2023,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1987-3682","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}